New drug combo tested to fight aggressive blood cancer
NCT ID NCT03623373
Summary
This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) for people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The goal was to see if adding acalabrutinib to the standard treatment was safe and more effective at shrinking the cancer before a planned stem cell transplant. Researchers enrolled 13 patients who were eligible for a transplant to measure how well the treatment worked and its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.